$ALLR
Allarity Therapeutics, Inc. Stock $allr

$allr Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022062840 Filed on October 07, 2022

Income Statement

Concept	2022 Q4	2022 Q2	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.245M	$2.927M	$6.220M
YoY Change	-63.91%	-16.87%	626.64%
% of Gross Profit
Research & Development	$941.0K	$1.402M	$9.522M
YoY Change	-90.12%	-57.76%	471.55%
% of Gross Profit
Depreciation & Amortization	$2.000K	$24.00K	$16.00K
YoY Change	-87.5%		-125.0%
% of Gross Profit
Operating Expenses	$3.186M	$4.329M	$15.74M
YoY Change	-79.76%	-36.71%	524.19%
Operating Profit		-$4.842M
YoY Change		10.65%
Interest Expense	$3.609M	$476.0K	-$91.00K
YoY Change	-4065.93%	-183.66%	-108.78%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$800.0K	-$954.0K
YoY Change	-100.0%	-7.73%	4670.0%
Pretax Income	-$3.141M	-$4.653M	-$16.78M
YoY Change	-81.28%	-44.72%	940.42%
Income Tax	-$303.0K	$4.000K	$35.00K
% Of Pretax Income
Net Earnings	-$3.102M	-$4.657M	-$16.82M
YoY Change	-81.55%	-45.08%	911.24%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.72
Diluted Earnings Per Share	-$0.28	-$516.5K	-$13.92M
COMMON SHARES
Basic Shares Outstanding	10.26M shares	9.017M shares	0.000 shares
Diluted Shares Outstanding		9.017M shares

Balance Sheet

Concept	2022 Q4	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.080M	$7.639M	$19.61M
YoY Change	-89.39%
Cash & Equivalents	$2.029M	$7.639M	$19.56M
Short-Term Investments	$51.00K		$53.00K
Other Short-Term Assets	$1.559M	$1.112M	$101.0K
YoY Change	1443.56%
Inventory
Prepaid Expenses	$591.0K	$876.0K	$36.00K
Receivables
Other Receivables
Total Short-Term Assets	$4.968M	$10.08M	$21.05M
YoY Change	-76.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.00K	$47.00K	$94.00K
YoY Change	-77.66%
Goodwill
YoY Change
Intangibles	$9.549M	$12.81M	$28.14M
YoY Change	-66.06%
Long-Term Investments	$0.00	$254.0K	$350.0K
YoY Change	-100.0%
Other Assets
YoY Change
Total Long-Term Assets	$9.576M	$13.11M	$28.58M
YoY Change	-66.49%
TOTAL ASSETS
Total Short-Term Assets	$4.968M	$10.08M	$21.05M
Total Long-Term Assets	$9.576M	$13.11M	$28.58M
Total Assets	$14.54M	$23.19M	$49.63M
YoY Change	-70.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.251M	$5.555M	$698.0K
YoY Change	795.56%
Accrued Expenses	$1.904M	$1.212M	$8.688M
YoY Change	-78.08%
Deferred Revenue
YoY Change
Short-Term Debt	$2.644M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.22M	$11.19M	$20.72M
YoY Change	-45.84%
LONG-TERM LIABILITIES
Long-Term Debt	$1.083M	$1.031M	$979.0K
YoY Change	10.62%
Other Long-Term Liabilities	$0.00	$0.00	$7.190M
YoY Change	-100.0%
Total Long-Term Liabilities	$1.083M	$1.031M	$8.169M
YoY Change	-86.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.22M	$11.19M	$20.72M
Total Long-Term Liabilities	$1.083M	$1.031M	$8.169M
Total Liabilities	$12.65M	$12.88M	$30.85M
YoY Change	-58.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$82.55M	-$74.68M	-$66.49M
YoY Change	24.15%
Common Stock	$2.000K	$1.000K	$1.000K
YoY Change	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$113.0K	$10.32M	$18.78M
YoY Change
Total Liabilities & Shareholders Equity	$14.54M	$23.19M	$49.63M
YoY Change	-70.7%

Cashflow Statement

Concept	2022 Q4	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.102M	-$4.657M	-$16.82M
YoY Change	-81.55%	-45.08%	911.24%
Depreciation, Depletion And Amortization	$2.000K	$24.00K	$16.00K
YoY Change	-87.5%		-125.0%
Cash From Operating Activities	-$2.446M	-$3.909M	-$4.483M
YoY Change	-45.44%		83.65%
INVESTING ACTIVITIES
Capital Expenditures	$18.00K		$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$18.00K	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$1.511M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.000M	-2.311M	18.44M
YoY Change	-94.58%		582.13%
NET CHANGE
Cash From Operating Activities	-2.446M	-3.909M	-4.483M
Cash From Investing Activities	-18.00K	0.000	0.000
Cash From Financing Activities	1.000M	-2.311M	18.44M
Net Change In Cash	-1.464M	-6.220M	13.96M
YoY Change	-110.49%		5288.03%
FREE CASH FLOW
Cash From Operating Activities	-$2.446M	-$3.909M	-$4.483M
Capital Expenditures	$18.00K		$0.00
Free Cash Flow	-$2.464M		-$4.483M
YoY Change	-45.04%		83.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
	dei	City Area Code CityAreaCode	(401)
	us-gaap	Stock Issued1 StockIssued1		usd
	allr	Conversion Of Derivative Liability To Equity ConversionOfDerivativeLiabilityToEquity		usd
	allr	Credit Risk Percentage CreditRiskPercentage	0.01	pure
	allr	Noncash Derivative Warrant Liability Costs NoncashDerivativeWarrantLiabilityCosts		usd
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
	allr	Right Of Use Asset Modification RightOfUseAssetModification		usd
CY2021Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability		usd
	allr	Series A Convertible Preferred Stock SeriesAConvertiblePreferredStock		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41160
	dei	Entity Registrant Name EntityRegistrantName	ALLARITY THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2147982
	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 Broadway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Local Phone Number LocalPhoneNumber	426-4664
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	ALLR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10260157	shares
CY2022Q2	us-gaap	Cash Cash	7677000	usd
CY2021Q4	us-gaap	Cash Cash	19555000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	235000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	625000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	876000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36000	usd
CY2022Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	1331000	usd
CY2021Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	838000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	10119000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21054000	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	254000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	350000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	86000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12811000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28135000	usd
CY2022Q2	us-gaap	Assets Assets	23231000	usd
CY2021Q4	us-gaap	Assets Assets	49633000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5555000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	698000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1429000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8590000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	23000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	60000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	54000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98000	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2882000	usd
CY2022Q2	allr	Warrant Liability WarrantLiability	1519000	usd
CY2021Q4	allr	Warrant Liability WarrantLiability	11273000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11462000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20719000	usd
CY2022Q2	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	1031000	usd
CY2021Q4	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	979000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	656000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1961000	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	7181000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	13149000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30849000	usd
CY2022Q2	allr	Convertible Preferred Stock ConvertiblePreferredStock	2116000	usd
CY2021Q4	allr	Convertible Preferred Stock ConvertiblePreferredStock	632000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9283295	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9283295	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8096014	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8096014	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83868000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85243000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1228000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-600000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74675000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66492000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7966000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18152000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23231000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49633000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1696000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2279000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2985000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3531000	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	14007000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3146000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2097000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6159000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3307000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4842000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	4376000	usd
	us-gaap	Operating Expenses OperatingExpenses	23151000	usd
	us-gaap	Operating Expenses OperatingExpenses	6838000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4842000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4376000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23151000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6838000	usd
	allr	Proceeds From Sales Of Ip ProceedsFromSalesOfIP	-1780000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	usd
CY2022Q2	allr	Interests Expense InterestsExpense	-33000	usd
CY2021Q2	allr	Interests Expense InterestsExpense	-166000	usd
	allr	Interests Expense InterestsExpense	-72000	usd
	allr	Interests Expense InterestsExpense	-245000	usd
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-393000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-480000	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-34000	usd
CY2021Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-67000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-70000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-180000	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-269000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-41000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-538000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-80000	usd
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	874000	usd
CY2021Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-25000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	13440000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	20000	usd
CY2022Q2	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability	800000	usd
	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability	800000	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-25000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-141000	usd
CY2021Q2	allr	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	273000	usd
	allr	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	474000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-257000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-990000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13745000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1580000	usd
CY2022Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-5099000	usd
CY2021Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-5366000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-9406000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-8418000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1223000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5103000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5396000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8183000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8481000	usd
	allr	Deemed Dividend Percentage1 DeemedDividendPercentage1	0.08	pure
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1572000	usd
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1377000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1511000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6480000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5396000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11266000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8481000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.3
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.78
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9016754	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5017183	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8654574	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4776643	shares
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-5103000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-5396000	usd
	us-gaap	Profit Loss ProfitLoss	-8183000	usd
	us-gaap	Profit Loss ProfitLoss	-8481000	usd
CY2022Q2	allr	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustment And Tax Noncontrolling Interest1 OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentAndTaxNoncontrollingInterest1	414000	usd
CY2021Q2	allr	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustment And Tax Noncontrolling Interest1 OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentAndTaxNoncontrollingInterest1	300000	usd
	allr	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustment And Tax Noncontrolling Interest1 OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentAndTaxNoncontrollingInterest1	628000	usd
	allr	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustment And Tax Noncontrolling Interest1 OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentAndTaxNoncontrollingInterest1	759000	usd
CY2021Q2	allr	Change In Fair Value Attributable To Instrument Specific Credit Risk ChangeInFairValueAttributableToInstrumentSpecificCreditRisk	3000	usd
	allr	Change In Fair Value Attributable To Instrument Specific Credit Risk ChangeInFairValueAttributableToInstrumentSpecificCreditRisk	9000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5517000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5699000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8811000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9249000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24439000	usd
CY2021Q1	allr	Stock Issued During Period Value Debt Conversion1 StockIssuedDuringPeriodValueDebtConversion1	2384000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	195000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-459000	usd
CY2021Q1	allr	Stock Issued During Period Fair Value Of Instrument Specific Credit Risk StockIssuedDuringPeriodFairValueOfInstrumentSpecificCreditRisk	-6000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3085000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	23468000	usd
CY2021Q2	allr	Stock Issued During Period Value Debt Conversion1 StockIssuedDuringPeriodValueDebtConversion1	496000	usd
CY2021Q2	allr	Units Issued For Cash UnitsIssuedForCash	12109000	usd
CY2021Q2	allr	Stock Issued During Period Value Shares Issued For Cash Exercise Of Warrants StockIssuedDuringPeriodValueSharesIssuedForCashExerciseOfWarrants	16000	usd
CY2021Q2	allr	Stock Issued During Fair Value Of Investor Warrants StockIssuedDuringFairValueOfInvestorWarrants	-2000000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	393000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	433000	usd
CY2021Q2	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	-300000	usd
CY2021Q2	allr	Stock Issued During Period Fair Value Of Instrument Specific Credit Risk StockIssuedDuringPeriodFairValueOfInstrumentSpecificCreditRisk	-3000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5396000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29216000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18152000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	62000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-133000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	452000	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1572000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1065000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-214000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3080000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14732000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	26000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-1377000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	161000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-59000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-414000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5103000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7966000	usd
	us-gaap	Profit Loss ProfitLoss	-8183000	usd
	us-gaap	Profit Loss ProfitLoss	-8481000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1780000	usd
	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability	800000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14007000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	628000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-538000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-80000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-480000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	52000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	48000	usd
	allr	Lossgain On Investment LossgainOnInvestment	-70000	usd
	allr	Lossgain On Investment LossgainOnInvestment	-180000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	474000	usd
	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	141000	usd
	allr	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-13440000	usd
	allr	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-20000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1223000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-355000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	311000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	593000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	474000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	887000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-156000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5175000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	222000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5820000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	76000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-34000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-53000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-62000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9963000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6833000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	809000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	809000	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-23000	usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	1511000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	-800000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12109000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	121000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1140000	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	2858000	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2944000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2311000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13035000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11465000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6202000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-413000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19555000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	298000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7677000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6598000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
	us-gaap	Interest Paid Net InterestPaidNet	20000	usd
	us-gaap	Interest Paid Net InterestPaidNet	55000	usd
	allr	Gain On Sale Of Ip GainOnSaleOfIP	971000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	701000	usd
	allr	Deemeds Dividend Percentage DeemedsDividendPercentage	0.08	pure
	us-gaap	Stock Issued1 StockIssued1	1572000	usd
	allr	Conversion Of Derivative Liability To Equity ConversionOfDerivativeLiabilityToEquity	2825000	usd
	allr	Noncash Derivative Warrant Liability Costs NoncashDerivativeWarrantLiabilityCosts	55000	usd
	allr	Right Of Use Asset Modification RightOfUseAssetModification	145000	usd
	allr	Financial Term FinancialTerm	P1Y
CY2022Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	74700000	usd
CY2021Q2	allr	Stock Issued During Fair Value Of Investor Warrants1 StockIssuedDuringFairValueOfInvestorWarrants1	2000000	usd
	allr	Stock Issued During Fair Value Of Investor Warrants1 StockIssuedDuringFairValueOfInvestorWarrants1	2100000	usd
CY2021Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	206000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	393000	usd
	us-gaap	Error Corrections And Prior Period Adjustments Description ErrorCorrectionsAndPriorPeriodAdjustmentsDescription	To correct this error, the Company made adjustments to (1) increase the January 1, 2021 deferred tax liability and deficit by $1,532; (2) increase the deferred tax liability as of June 30, 2021 by $288; (3) increase income tax receivable by $93; and (4) reduce the tax benefit for the three months ended June 30, 2021 by $403 and by $718 for the six months ended June 30, 2021 in the consolidated statement of operations and comprehensive loss.
CY2021Q2	allr	Investment Tax Credits InvestmentTaxCredits	219000	usd
	allr	Investment Tax Credits InvestmentTaxCredits	438000	usd
CY2021	allr	Other Operating Activities Cash Flow Statements OtherOperatingActivitiesCashFlowStatements	-187000	usd
CY2021	us-gaap	Effect On Future Cash Flows Amount EffectOnFutureCashFlowsAmount	-27000	usd
CY2021	allr	Effect Of Exchange Rate On Cash1 EffectOfExchangeRateOnCash1	214000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	36000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(a) Use of Estimates and Assumptions</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting years. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the Series A preferred shares, warrants, convertible debt, and the accrual for research and development expenses, fair values of acquired intangible assets and impairment review of those assets, share based compensation expense, and income tax uncertainties and valuation allowances. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering reasonable changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known and if material, their effects are disclosed in the notes to the condensed consolidated financial statements. Actual results could differ from those estimates or assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(c) Concentrations of credit risk and of significant suppliers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is not significant. The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><i> </i></p>
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4776643	shares
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-414000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-300000	usd
CY2022Q2	allr	Aoci Market Risk Benefit Instrument Specific Credit Risks Before Tax AociMarketRiskBenefitInstrumentSpecificCreditRisksBeforeTax	0	usd
CY2021Q2	allr	Aoci Market Risk Benefit Instrument Specific Credit Risks Before Tax AociMarketRiskBenefitInstrumentSpecificCreditRisksBeforeTax	-3000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-628000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-759000	usd
	allr	Aoci Market Risk Benefit Instrument Specific Credit Risks Before Tax AociMarketRiskBenefitInstrumentSpecificCreditRisksBeforeTax	0	usd
	allr	Aoci Market Risk Benefit Instrument Specific Credit Risks Before Tax AociMarketRiskBenefitInstrumentSpecificCreditRisksBeforeTax	-9000	usd
CY2021	allr	Net Other Current Asset NetOtherCurrentAsset	625000	usd
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5017183	shares
CY2022Q2	us-gaap	Deposit Assets DepositAssets	51000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	53000	usd
CY2022Q2	allr	Salary Deposit SalaryDeposit	83000	usd
CY2021Q4	allr	Salary Deposit SalaryDeposit	65000	usd
CY2022Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	101000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	507000	usd
	allr	Net Other Current Asset NetOtherCurrentAsset	235000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	818000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	14000	usd
CY2022Q2	allr	Other Prepayments OtherPrepayments	58000	usd
CY2021Q4	allr	Other Prepayments OtherPrepayments	22000	usd
CY2022Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	876000	usd
	allr	Fair Market Value FairMarketValue	254000	usd
	us-gaap	Gain Loss Recognized On Assets Transferred To Separate Account GainLossRecognizedOnAssetsTransferredToSeparateAccount	96000	usd
	us-gaap	Gain Loss On Components Excluded From Assessment Of Foreign Currency Cash Flow Hedge Effectiveness GainLossOnComponentsExcludedFromAssessmentOfForeignCurrencyCashFlowHedgeEffectiveness	26000	usd
	us-gaap	Gain Loss Recognized On Assets Transferred To Separate Account GainLossRecognizedOnAssetsTransferredToSeparateAccount	180000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	350000	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	845000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	336000	usd
CY2022Q2	allr	Translation Effects TranslationEffects	-324000	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	96000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	495000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	254000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	350000	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	329000	usd
CY2021Q4	allr	Translation Effects TranslationEffects	-328000	usd
CY2022Q2	allr	Total Property Equipment TotalPropertyEquipment	5000	usd
CY2021Q4	allr	Total Property Equipment TotalPropertyEquipment	8000	usd
	us-gaap	Depreciation Depreciation	47000	usd
	us-gaap	Depreciation Depreciation	53000	usd
	allr	Intangible Assets Utilizing A Discounted IntangibleAssetsUtilizingADiscounted	0.16	pure
	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	14007000	usd
CY2022Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	12811000	usd
CY2021Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	28135000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	263000	usd
CY2022Q2	allr	Development Cost Liability DevelopmentCostLiability	54000	usd
CY2021Q4	allr	Development Cost Liability DevelopmentCostLiability	6750000	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	776000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1088000	usd
CY2022Q2	allr	Accrued Board Member Fees AccruedBoardMemberFees	74000	usd
CY2021Q4	allr	Accrued Board Member Fees AccruedBoardMemberFees	54000	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	199000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	316000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	326000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	382000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1429000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8590000	usd
CY2022Q2	allr	Principal Amount PrincipalAmount	1000000	usd
	allr	Noncreditable Upfront Payment NoncreditableUpfrontPayment	1000000	usd
	allr	Promissory Note PromissoryNote	1000000	usd
CY2022Q2	allr	Interest Payable Percentage InterestPayablePercentage	0.05	pure
CY2019Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.12875	pure
CY2019	allr	Equivalent Market Interest Rate EquivalentMarketInterestRate	787000	usd
CY2020	us-gaap	Interest And Debt Expense InterestAndDebtExpense	93000	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	99000	usd
CY2021Q4	us-gaap	Guaranteed Benefit Liability Net GuaranteedBenefitLiabilityNet	979000	usd
CY2020Q4	us-gaap	Guaranteed Benefit Liability Net GuaranteedBenefitLiabilityNet	880000	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	215000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	27000	usd
CY2021	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	48000	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	812000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	785000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	194000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	143000	usd
	us-gaap	Accretion Expense AccretionExpense	25000	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	51000	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1031000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	979000	usd
CY2020Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10100000	usd
CY2020Q1	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	1010000	usd
CY2020Q1	allr	Tranche Cash Received Percentage TrancheCashReceivedPercentage	0.95	pure
CY2020Q1	allr	Conversion Price Percentage ConversionPricePercentage	0.05	pure
CY2020Q1	allr	Weighted Average Price Percentage weightedAveragePricePercentage	0.95	pure
CY2021Q2	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.15	pure
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	9000	usd
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1327000	usd
CY2021Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1140000	usd
	us-gaap	Servicing Liability At Fair Value Changes In Fair Value Resulting From Changes In Valuation Inputs Or Changes In Assumptions ServicingLiabilityAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions	474000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2825000	usd
CY2021Q2	allr	Sale Of Purchase Shares SaleOfPurchaseShares	20000	shares
CY2021Q2	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	20000000	usd
CY2021Q4	allr	Preferred Stock Descriptions PreferredStockDescriptions	On December 20, 2021, we issued 20,000 shares of Preferred Stock at $1,000 per share and a common stock purchase warrant to purchase 2,018,958 shares of common stock at an initial exercise price of $9.9061 to 3i for an aggregate purchase price of $20 million.
CY2021Q3	allr	Conversion Amount Percentage ConversionAmountPercentage	1.25	pure
CY2021Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	2500000	usd
CY2021Q3	allr	Dividend Equal Percentage DividendEqualPercentage	0.08	pure
CY2021Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	80000	usd
CY2021Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1080000	usd
CY2021Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.18	pure
	allr	Conversion Percentage ConversionPercentage	1.25	pure
CY2022Q2	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	539000	usd
CY2022Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	441005	shares
	allr	Issuance Of Warrants Purchased Shares IssuanceOfWarrantsPurchasedShares	2018958	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.9061
	allr	Fund Warrant Terms Description FundWarrantTermsDescription	(i)The warrants have and term of three years and expire on December 20, 2024; (ii) The exercise of the 3i Warrants are subject to a beneficial ownership limitation of 4.99% which can be adjusted to a beneficial ownership limitation of 9.99% upon sixty-one (61) days’ prior written notice;
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	613000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1511000	usd
CY2022Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	1511000	usd
	us-gaap	Debt Instrument Description DebtInstrumentDescription	Additionally, because the Company’s average daily dollar volume of stock trading was less than $2.5 million during a ten-day period in January 2022, the Company has recorded a one-time deemed dividend of 8% in the amount of $1,572 on preferred stock converted between February 1, 2022 and March 31, 2022 and the balance of Series A Preferred Stock outstanding as at March 31, 2022 as an increase to the value of the Series A Preferred Stock and a reduction of additional paid in capital. In addition, under the terms of the Registration Rights Agreement (“RRA”), during the period ended June 30, 2022, the Company has also paid 3i an additional $800 in Registration Delay Payments.
CY2022Q2	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-1187000	usd
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1377000	usd
CY2022Q2	allr	Common Stock Description CommonStockDescription	(a)Units consisting of 2,417,824 common shares and 2,417,824 common share purchase warrants for $5 per unit; valued at $12,109 in exchange for $12,109 in cash, pursuant to its June 2021 rights offering. The attached warrants are exercisable for $10 each with an original expiration date of April 15, 2023, subsequently amended to September 13, 2021; (b)5,433 common shares valued at $16 upon the exercise of common stock purchase warrants; and (c)99,383 common shares valued at $496 upon conversion of debt. Pursuant to the terms of the June rights offering the Company also recorded an obligation to issue 482,250 common shares and 482,250 common share purchase units valued at $2,384 in consideration for services ($1,991 net of $393 in associated costs). The units were issued after June 2021.
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1519000	usd
CY2021	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	11273000	usd
CY2021Q2	allr	Granted To Investors Shares GrantedToInvestorsShares	2417824	shares
CY2021Q2	allr	Rights Of Warrants RightsOfWarrants	10
CY2021Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3504582	shares
CY2021Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	1086758	shares
CY2021Q2	allr	Warrants Excercise Price WarrantsExcercisePrice	36
CY2022Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	39000	usd
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	20000	usd
CY2021Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	285000	usd
CY2021Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	147000	usd
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	441005	shares
CY2022Q2	allr	Gross Value1 GrossValue1	190000	usd
	allr	Common Stock Description CommonStockDescription	(b)5,433 common shares valued at $16 upon the exercise of common stock purchase warrants; and (c)99,383 common shares valued at $496 upon conversion of debt. Pursuant to the terms of the June rights offering the Company also recorded an obligation to issue 482,250 common shares and 482,250 common share purchase units valued at $2,384 in consideration for services ($1,991 net of $393 in associated costs). The units were issued after June 2021. During the six months ended June 30, 2022, the Company issued 1,187,281 shares of common stock valued at $705 gross and ($806) net of the $1,511 floor price adjustment paid in cash upon the conversion of 2,782 shares of Series A Preferred stock. During the six months ended June 30, 2021, the Company issued: (a)Units consisting of 2,417,824 common shares valued at $12,125 upon the issuance of 2,417,824 units of one common share and one share purchase warrant for $10.0 per unit. Terms of the Units and the obligation to issue shares of $2,384 are as described above in the three months ended June 30, 2021; (b)5,433 common shares valued at $16 upon the exercise of options for common stock; and (c)628,193 common shares valued at $2,880 upon conversion of debt.
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1187281	shares
	allr	Gross Value1 GrossValue1	705000	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-806000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1511000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	59000	usd
CY2022Q2	us-gaap	Other Expenses OtherExpenses	790000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	848000	usd
CY2021Q2	us-gaap	Other General Expense OtherGeneralExpense	433000	usd
	allr	Common Shares CommonShares	43898	shares
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1006000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	628000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	664000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	342000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	414000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	214000	usd
CY2022Q2	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	1601000	usd
	allr	Realized Over Period RealizedOverPeriod	P2Y
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5433	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.6
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	8868000	usd
CY2021Q4	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	7181000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3031977	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3714668	shares
	allr	Series A Convertible Preferred Stock SeriesAConvertiblePreferredStock	9276923	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	12308900	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	3714668	shares
CY2022Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	254000	usd
CY2022Q2	allr	Warrant Liability WarrantLiability	1519000	usd
CY2022Q2	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	2882000	usd
CY2022Q2	us-gaap	Credit Risk Derivative Liabilities At Fair Value CreditRiskDerivativeLiabilitiesAtFairValue	4401000	usd
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	350000	usd
CY2021Q4	allr	Warrant Liability WarrantLiability	11273000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2021Q4	us-gaap	Credit Risk Derivative Liabilities At Fair Value CreditRiskDerivativeLiabilitiesAtFairValue	18454000	usd
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	1519000	usd
CY2021	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	11273000	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	14007000	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	1223000	usd
CY2021	us-gaap	Development Costs DevelopmentCosts	1264000	usd
	allr	Cancellation Liability CancellationLiability	1309	usd
	allr	Agreement Amount AgreementAmount	338	usd
	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	971000	usd
CY2022Q2	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	338000	usd
	allr	Royalty Payments Description RoyaltyPaymentsDescription	i.a one-time upfront payment of $250 and $100 for stenoparib and dovitinib respectively, within 5 business days after January 2, 2022 ($350 received as of January 11, 2022, and recorded in other income as proceeds on sale of IP ); and ii. two milestone payments of $1,000 each due and payable upon receipt of regulatory approval of a product in the United States, and of a product in Europe, respectively. Pursuant to the Oncoheroes Agreement Allarity is also entitled to tiered royalties on aggregate net product sales (“Sales”) of between 7% and 12% on net sales of products as follows: 7% on Sales less than $100 million; 10% on Sales of greater than $100 million and less than $200 million; and 12% on Sales greater than $200 million.
	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	1000000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	459000	usd
	allr	Milestone Payment MilestonePayment	500000	usd
CY2022Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5000000	usd
	allr	Obligated To Pay ObligatedToPay	26500000	usd
	allr	Floor Price FloorPrice	1.9812
CY2022Q2	allr	Conversion Floor Amount ConversionFloorAmount	1598000	usd
	allr	Net Proceeds NetProceeds	182000	usd
	allr	Recognized A Loss RecognizedALoss	72000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2021Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022Q2	allr	Proceeds From Sales Of Ip ProceedsFromSalesOfIP		usd
CY2021Q2	allr	Proceeds From Sales Of Ip ProceedsFromSalesOfIP		usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	allr	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt		usd
	allr	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt		usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2021Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8654574	shares
CY2022Q2	allr	Change In Fair Value Attributable To Instrument Specific Credit Risk ChangeInFairValueAttributableToInstrumentSpecificCreditRisk		usd
	allr	Change In Fair Value Attributable To Instrument Specific Credit Risk ChangeInFairValueAttributableToInstrumentSpecificCreditRisk		usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit		usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	allr	Gain On Sale Of Ip GainOnSaleOfIP		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001860657

Files In Submission

Name	View Source	Status
0001213900-22-062840-index-headers.html	Edgar Link	pending
0001213900-22-062840-index.html	Edgar Link	pending
0001213900-22-062840.txt	Edgar Link	pending
0001213900-22-062840-xbrl.zip	Edgar Link	pending
allr-20220630.xsd	Edgar Link	pending
ex10-5_001.jpg	Edgar Link	pending
ex10-6_001.jpg	Edgar Link	pending
f10q0622ex10-5_allarity.htm	Edgar Link	pending
f10q0622ex10-6_allarity.htm	Edgar Link	pending
f10q0622ex10-7_allarity.htm	Edgar Link	pending
f10q0622ex31-1_allarity.htm	Edgar Link	pending
f10q0622ex31-2_allarity.htm	Edgar Link	pending
f10q0622ex32-1_allarity.htm	Edgar Link	pending
allr-20220630_pre.xml	Edgar Link	unprocessable
allr-20220630_cal.xml	Edgar Link	unprocessable
allr-20220630_lab.xml	Edgar Link	unprocessable
allr-20220630_def.xml	Edgar Link	unprocessable
f10q0622ex32-2_allarity.htm	Edgar Link	pending
f10q0622_allaritytherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
f10q0622_allaritytherap_htm.xml	Edgar Link	completed
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLR
Allarity Therapeutics, Inc. Stock $allr

2022 Q4 Form 10-Q Financial Statement

#000121390022062840 Filed on October 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLR Allarity Therapeutics, Inc. Stock $allr

2022 Q4 Form 10-Q Financial Statement

#000121390022062840 Filed on October 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLR
Allarity Therapeutics, Inc. Stock $allr